Therefore, the retrospective post-hoc analysis evaluated 134 adults at Tygerberg Hospital over one year, comparing potassium responses at 24 hours and 2–7 days while excluding patients on kidney replacement therapy. Using analysis of variance and multilinear regression, researchers assessed the primary endpoint of absolute potassium reduction in patients with baseline levels below 5.5 mmol/L.
Key Clinical Findings of the Study Include:
Initial Latency: The investigation discovered that within the first 24 hours, there were no statistically significant differences in potassium reduction between the groups, with the combination group showing a median decrease of -1.3 mmol/L
Subacute Efficacy: By the second to seventh day of therapy, the research demonstrated that the combination group achieved a superior absolute potassium reduction of -1.75 mmol/L, whereas the lactulose-only group saw a more modest decline of -0.9 mmol/L.
Predictive Factors: Multivariable analysis from the trial identified that the baseline potassium level was the most significant independent predictor of success, where every 1 mmol/L increase at the start resulted in a 0.87 mmol/L greater reduction over the follow-up period.
Comorbidity Correlation: The study noted that while all patients in the combination group suffered from kidney dysfunction, sensitivity analyses confirmed that the observed potassium drops remained robust even after adjusting for the severity of chronic kidney disease.
Resource Pragmatism: The analysis observed that in low-resource settings where newer, expensive potassium binders are unavailable, the combination of these older agents provides a pragmatic option for subacute management.
The results suggest that among hospitalized patients suffering from hyperkalaemia, utilizing both lactulose and SPS is associated with a more pronounced reduction in serum potassium by day seven, though the study clarifies that the high baseline potassium concentration of 7.2 mmol/L in the combination group was the primary driver of this trend.
These findings suggest that clinicians might find value in pairing osmotic laxatives with traditional resins to optimize gastrointestinal potassium clearance, particularly when managing subacute cases in resource-limited environments.
While the retrospective nature and lack of specific dosing information represent notable constraints, the findings emphasize the importance of future prospective randomized controlled trials to definitively establish the safest and most effective dosing strategies for this combined therapeutic approach.
Reference
Esaadi M, Davids MR, Chothia MY. Potassium Reduction Associated with Lactulose and Sodium Polystyrene Sulfonate Use in Hospitalized Patients with Hyperkalemia: A Real-World Observational Study. Indian Journal of Nephrology. 2026;.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.